REGENXBIO Announces Regulatory Update on RGX-121 for MPS II

Summary

REGENXBIO announced a regulatory update on RGX-121 (clemidsogene lanparvovec), its investigational gene therapy for Mucopolysaccharidosis type II (MPS II), also known as Hunter Syndrome. The article text is incomplete and does not provide details on the specific regulatory outcome or decision date.